Synonym: N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine; N6-[(4-nitrophenyl)methyl]-N2-[[3-(trifluoromethyl)phenyl]methyl]-9H-Purine-2,6-diamine; N6-[(4-nitrophenyl)methyl]-N2-[[3-(trifluoromethyl)phenyl]methyl]-1H-Purine-2,6-diamine
CAS Number: 519178-28-0
Empirical Formula (Hill Notation): C20H16F3N7O2
Molecular Weight: 443.38
MDL Number: MFCD16875436
Linear Formula: C20H16F3N7O2
Product Type: Chemical
| assay |
≥95% (HPLC) |
| color |
yellow |
| form |
powder |
| InChI |
1S/C20H16F3N7O2/c21-20(22,23)14-3-1-2-13(8-14)10-25-19-28-17(16-18(29-19)27-11-26-16)24-9-12-4-6-15(7-5-12)30(31)32/h1-8,11H,9-10H2,(H3,24,25,26,27,28,29) |
| InChI key |
DDSBPUYZPWNNGH-UHFFFAOYSA-N |
| originator |
Novartis |
| Quality Level |
100  |
| SMILES string |
[O-][N+](=O)c1ccc(CNc2nc(NCc3cccc(c3)C(F)(F)F)nc4[nH]cnc24)cc1 |
| solubility |
DMSO: ≥10 mg/mL |
| storage condition |
protect from light |
| storage temp. |
2-8°C |
| Biochem/physiol Actions: |
TNP is a potent and selective IP6K inhibitor; less selective inhibitor of IP3K. Discovery of TNP as an inositol trisphosphate (IP3) kinase inhibitor was first reported in 2002, However, a recent reference shows that TNP is more potent as an IP6K inhibitor, making it valuable for study of inositol pyrophosphates. |
| Features and Benefits: |
This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
5, 25 mg in glass bottle |
| Preparation Note: |
TNP is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml. |
| Hazard Codes |
T |
| Risk Statements |
25-36 |
| Safety Statements |
26-45 |
| RIDADR |
UN 2811 6.1 / PGIII |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥95% (HPLC) |
| Storage Temp. |
2-8°C |
| UNSPSC |
12352200 |
